Review
Open access
Oct 2026
From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver condition worldwide, reflecting the growing global burden of obesity and type 2 diabetes (T2D). The complex pathophysiology of MASLD, characterized by insulin resistance (IR), lipotoxicity, and chronic low-g...
C. Argano, Dalila Maggio, Chiara Pollicino et al.
· Frontiers in Pharmacology · 0 citations